References
- Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135–1146.
- Ministry of Public Health, Kingdom of Thailand. Guidelines for the care of thalassemia patients in general practice. 1st ed. Nonthaburi, Thailand: WVOP Thai Printing; 2017.
- Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK thalassaemia register. Lancet. 2000;355(9220):2051–2052.
- Mokhtar GM, Gadallah M, El Sherif NHK, et al. Morbidities and mortality in transfusion-dependent beta-thalassemia patients (single-center experience). Pediatr Hematol Oncol. 2013;30(2):93–103.
- Michael A. Guidelines for the management of transfusion dependent thalassaemia [TDT]. 3rd ed. Nicosia, Cyprus: Thalassaemia International Federation; 2014.
- Pakbaz Z, Fischer R, Treadwell M, et al. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia. Ann NY Acad Sci. 2005;1054:486–491.
- Trachtenberg F, Vichinsky E, Haines D, et al. Thalassemia clinical research network. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol. 2011;86(5):433–436.
- Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertension. 2008;10(5):348–354.
- El-Rachidi S, LaRochelle JM, Morgan JA. Pharmacists and pediatric medication adherence: bridging the gap. Hosp Pharm. 2017;52(2):124–131.
- Al-Kloub MI, Salameh TN, Froelicher ES. Impact of psychosocial status and disease knowledge on deferoxamine adherence among thalassaemia major adolescents. Int J Nurs Pract. 2014;20(3):265–274.